ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,887Medicare Part D Prescriptions Filled, Including Refills

Rank: 92 out of 1269

$469K Total Retail Price of All Prescriptions

Rank: 173 out of 1269

332 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
58% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 332 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

5% of this provider’s 332 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

0% of this provider’s 6,631 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
PRAVASTATIN SODIUM 528 382 1 11
LEVOTHYROXINE SODIUM 427 337 2 4
LISINOPRIL 263 197 3 1
OMEPRAZOLE 223 136 4 8
LOSARTAN POTASSIUM 222 189 5 15
FUROSEMIDE 206 169 6 5
AMLODIPINE BESYLATE 205 172 7 2
CARVEDILOL 174 154 8 29
ALLOPURINOL 172 119 9 49
METFORMIN HCL 131 91 10 9
SPIRONOLACTONE 129 86 11 77
FLUOXETINE HCL 121 81 12 83
POLYETHYLENE GLYCOL 3350 112 105 13 50
WARFARIN SODIUM 112 111 13 12
METOPROLOL TARTRATE 112 85 13 6
TRAMADOL HCL 109 98 16 16
GABAPENTIN 103 77 17 17
PANTOPRAZOLE SODIUM 94 53 18 18
ZOLPIDEM TARTRATE 92 66 19 19
PREDNISONE 92 81 19 45
GLIMEPIRIDE 80 48 21 57
POTASSIUM CHLORIDE 78 52 22 26
SIMVASTATIN 69 62 23 3
ATENOLOL 69 67 23 14
DILTIAZEM 24HR CD 69 54 23 146
NIFEDIPINE ER 68 43 26 65
ACARBOSE 66 51 27 284
CLOPIDOGREL 66 46 27 32
DOXYCYCLINE HYCLATE 65 49 29 214
QUINAPRIL HCL 64 55 30 167
FLUTICASONE PROPIONATE 63 43 31 40
OXYCODONE-ACETAMINOPHEN 62 42 S2 32 44
BUSPIRONE HCL 61 38 33 135
ADVAIR DISKUS 61 40 33 46
PLAVIX 61 48 33 47
HYDRALAZINE HCL 59 43 36 48
LIDODERM 59 59 36 56
AZITHROMYCIN 58 42 38 42
SERTRALINE HCL 56 32 39 23
MIRTAZAPINE 56 48 39 24
SINGULAIR 54 25 41 123
ATORVASTATIN CALCIUM 53 33 42 7
VENTOLIN HFA 52 11 43 100
RANITIDINE HCL 51 46 44 27
CARBIDOPA-LEVODOPA 50 50 45 78
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 21, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.